Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?

Annals of Clinical Microbiology and Antimicrobials
Tuna DemirdalSalih Atakan Nemli

Abstract

In the present study, our objective was to evaluate and compare the clinical and microbiological results in patients receiving systemic and systemic plus inhaled colistin therapy due to nosocomial pneumonia (NP) or ventilator associated pneumonia (VAP) caused by Acinetobacter baumannii. A retrospective matched case-control study was performed at the ICUs at Izmir Katip Celebi University Ataturk Training and Research Hospital from January 2013 to December 2014. Eighty patients who received only systemic colistin were matched 43 patients who received systemic colistin combined with inhaled therapy. In 97.6 % of the patients colistin was co-administered with at least one additional antibiotic. The most frequently co-administered antibiotics were carbapenems (79.7 %). The patient groups did not differ significantly in terms of the non-colistin antibiotics used for treatment (p > 0.05). Acute renal injury was observed in 53.8 % and 48.8 % of the patients who received parenteral colistin or parenteral plus inhaler colistin, respectively (p = 0.603). There were no significant differences between the groups in terms of clinical success (p = 0.974), clinical failure (p = 0.291), or recurrence (p = 0.094). Only, a significantly higher pa...Continue Reading

References

Jul 31, 2004·Annals of Clinical Microbiology and Antimicrobials·Mark E JonesRichard P Wenzel
Aug 18, 2004·Critical Care : the Official Journal of the Critical Care Forum·Rinaldo BellomoUNKNOWN Acute Dialysis Quality Initiative workgroup
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Jan 7, 2006·The Journal of Antimicrobial Chemotherapy·F RatjenH Grasemann
Mar 2, 2006·Critical Care : the Official Journal of the Critical Care Forum·Matthew E Falagas, Sofia K Kasiakou
Nov 11, 2008·American Journal of Infection Control·Jonathan R EdwardsUNKNOWN National Healthcare Safety Network Facilities
Sep 8, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·I P KorbilaM E Falagas
Mar 2, 2010·Infection·A Michalopoulos, E Papadakis
Aug 7, 2010·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Cheng-Chih LinChun-Ming Lee
Oct 27, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Diamantis P KofteridisGeorge Samonis
Oct 18, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S-C KuoC-P Fung
Feb 11, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Diana F FlorescuA C Kalil
May 31, 2012·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Gamze KalinMehmet Doganay
Jul 20, 2012·Intensive Care Medicine·Zoe E AthanassaGeorge J Baltopoulos
Dec 3, 2014·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Tai-Chin HsiehWen-Sen Lee
Dec 3, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Zahra KassamaliLarry H Danziger
Feb 3, 2015·Seminars in Respiratory and Critical Care Medicine·Cornelia B Landersdorfer, Roger L Nation
Feb 24, 2015·Journal of Intensive Care·Mohan Gurjar
Mar 3, 2015·Current Opinion in Pulmonary Medicine·Cristina Vazquez Guillamet, Marin H Kollef
Mar 19, 2015·Current Opinion in Pulmonary Medicine·Lucy B Palmer

❮ Previous
Next ❯

Citations

Nov 1, 2016·Expert Review of Anti-infective Therapy·Matthew P Schreiber, Andrew F Shorr
Aug 6, 2017·The Annals of Pharmacotherapy·G Christopher Wood, Joseph M Swanson
Dec 16, 2016·Clinical Microbiology Reviews·Darren WongBrad Spellberg
Dec 29, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Florian WagenlehnerJason M Pogue
Jun 3, 2021·Microorganisms·Yinggang ZhuUNKNOWN European Investigator Network for Nebulized Antibiotics in Ventilator-Associated Pneumonia (ENAVAP)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.